Yukito Ichinose - Concepedia

Author

Yukito Ichinose

National Hospital Organization Kyushu Cancer Center

Also Known As

Ichinose Yukito, Ichinose, Yukito, Y Ichinose, YUKITO ICHINOSE, YUKITO ICHINOSE, M.D., Yukito Ichinose

329

Publications

18.1K

Citations

H-Index

Concepts

All Affiliations

National Hospital Organization Kyushu Cancer Center Kyushu University Kindai University National Cancer Center Hospital East Shikoku Cancer Center

About

Yukito Ichinose is an author at National Hospital Organization Kyushu Cancer Center specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	84	4.1K
2	Health Sciences	20	26	1.7K
3	Engineering	1	1	17
4	Natural Sciences	1	1	14
5	Biomedical Engineering	1	1	24

Yukito Ichinose

145

Publications

17.4K

Citations

H-Index

Page 1

	Year	Citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung Harubumi Kato, Yukito Ichinose, Morio Ohta, New England Journal of Medicine	2004	828
Interstitial Lung Disease in Japanese Patients with Lung Cancer Shoji Kudoh, Harubumi Kato, Yutaka Nishiwaki, American Journal of Respiratory and Critical Care Medicine	2008	481
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Roy S. Herbst, Yan Sun, Wilfried Eberhardt, The Lancet Oncology Second-line TreatmentOncologyMetronomic TherapyDocetaxel Versus DocetaxelClinical Trials	2010	417
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, Journal of Clinical Oncology	2008	364
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas Miguel Tarón, Yukito Ichinose, Rafael Rosell, Clinical Cancer Research	2005	336
LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both Nobuyuki Katakami, Shinji Atagi, Kōichi Goto, Journal of Clinical Oncology	2013	323
Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group Kaoru Kubota, Koshiro Watanabe, Hideo Kunitoh, Journal of Clinical Oncology	2004	232
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR Masaru Watanabe, Tomoya Kawaguchi, Shun‐ichi Isa, Clinical Cancer Research	2015	222
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara, Lung Cancer	2012	211

Page 1